In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo International PLC

www.endo.com

Latest From Endo International PLC

Finance Watch: Polaris Piles On As Multiple Life Science VCs Raise New Funds

Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.

Financing StartUps and SMEs

Endo Slashes Loss Despite Generics Slide

Endo sharply reduced its net loss in the first quarter, beating analysts’ earnings forecasts. While generics sales slid, revenues from its higher-margin sterile injectables unit soared.

Sales & Earnings Generic Drugs

Opioid Litigation Avalanche: New York's Expanded Suit Puts More Pressure On Makers And Distributors

Complaint claims Sackler family transferred opioid profits to personal trusts; trials scheduled in federal multidistrict litigation and several state cases.

Legal Issues Policy

Athenex Sues FDA To Get Vasopressin On List Of Drugs That Can Be Compounded

Company argues there is a clinical need for its ready-to-use, preservative-free compounded formulation of vasopressin but agency says Vasostrict is available in a dose without the preservative.

FDA Legal Issues
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register